BCL2 and acute myeloid leukemia: Currently, there are ongoing mono and combination therapies targeting mitochondrial respiratory complexes or metabolites at the stage of experimental evaluation and clinical trials for AML, which include inhibitors of BCL-2, enzymes in the glycolysis and citric acid cycle, the electron transport chain (e.g., metformin), and glutamine or fatty acid pathways [45].